Morinaga & Co Ltd operates in the Candy & other confectionery products sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Morinaga & Co Ltd with three other
bakery and confectionary companies in Asia:
GlaxoSmithKline Consumer Healthcare Limited
sales of 43.09 billion Indian Rupees [US$645.88 million]
of which 100%
Imuraya Group Company Limited
(38.64 billion Japanese Yen [US$372.15 million]
of which 88%
was Distribution Business), and
Nakamuraya Co., Ltd.
(41.37 billion Japanese Yen [US$398.38 million]
of which 70%
was Confectionery Business).
Morinaga & Co Ltd reported sales of ¥181.87 billion (US$1.75 billion)
March of 2016.
increase of 2.2%
versus 2015, when the company's sales were ¥177.93 billion.
This was the fourth straight year of sales growth at Morinaga & Co Ltd.
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
17.7% in 2016, from
¥565.00 million to ¥665.00 million.
Morinaga & Co Ltd also saw significant increases in sales in
Food Products (up 3.2% to ¥172.43 billion)
Not all segments of Morinaga & Co Ltd experienced an increase in sales in 2016:
sales of Wholesale Food and Restaurant fell 19.0% to ¥6.21 billion.
(However, this segment's sales were only a very small portion of the company's overall sales).
Morinaga & Co Ltd also experienced decreases in sales in
Real Estate and Services (down 3.1% to ¥2.56 billion)